International Stem Cell Corporation is a biotechnology company currently focused on developing therapeutic and research products. In the area of therapeutic product development, ISCO's objective is to create an unlimited source of human cells for use in the treatment of several diseases, including diabetes, liver disease and retinal disease through cell transplant therapy. In furtherance of this objective, ISCO has developed pluripotent human stem cells from unfertilized human eggs, and techniques to cause those stem cells to be differentiated into the specific cell types required for transplant. It has developed manufacturing protocols to produce the cells minimizing contamination with animal by-products, a characteristic likely to be important in meeting U.S. Food and Drug Administration requirements. ISCO also provides the specialized cells and growth media needed for therapeutic cell transplantation research to academic and commercial researchers in related fields.
| Revenue (Most Recent Fiscal Year) | $9.09M |
| Net Income (Most Recent Fiscal Year) | $-0.21M |
| PE Ratio (Current Year Earnings Estimate) | -- |
| PE Ratio (Trailing 12 Months) | -- |
| PEG Ratio (Long Term Growth Estimate) | -- |
| Price to Sales Ratio (Trailing 12 Months) | 0.11 |
| Price to Book Ratio (Most Recent Quarterly Book Value per Share) | -- |
| Price to Cash Ratio (Most Recent Annual Cash Flow per Share) | -- |
| Pre-Tax Margin (Trailing 12 Months) | -2.76% |
| Net Margin (Trailing 12 Months) | -3.39% |
| Return on Equity (Trailing 12 Months) | -- |
| Return on Assets (Trailing 12 Months) | -5.71% |
| Current Ratio (Most Recent Fiscal Quarter) | 0.75 |
| Quick Ratio (Most Recent Fiscal Quarter) | 0.51 |
| Debt to Common Equity (Most Recent Fiscal Quarter) | -- |
| Inventory Turnover (Trailing 12 Months) | 2.97 |
| Book Value per Share (Most Recent Fiscal Quarter) | $-0.51 |
| Earnings per Share (Most Recent Fiscal Quarter) | -- |
| Earnings per Share (Most Recent Fiscal Year) | -- |
| Diluted Earnings per Share (Trailing 12 Months) | $-0.04 |
| Exchange | -- |
| Sector | -- |
| Industry | -- |
| Common Shares Outstanding | 8.00M |
| Free Float | 1.48M |
| Market Capitalization | $0.96M |
| Average Volume (Last 20 Days) | 2571.05 |
| Beta (Past 60 Months) | -0.02 |
| Percentage Held By Insiders (Latest Annual Proxy Report) | 81.48% |
| Percentage Held By Institutions (Latest 13F Reports) | 0.00% |
| Annual Dividend (Based on Last Quarter) | $0.00 |
| Dividend Yield (Based on Last Quarter) | 0.00% |